BYOMass Inc

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Our mission is to:
*Harness human biology
*Target causative mechanisms
*Deliver novel therapeutics
*Transform patient lives
BYOMass is pioneering a precision medicine approach to treat patients where dysregulation of specific superfamily members play a major role in their disease. Our approach to building a therapeutic pipeline follows these principles:
*Efficacy: Harnessing human biology and causal mechanisms of disease for transformative efficacy
*Avoiding known toxicities associated with directly blocking TGF-β or subfamily receptors
*Preclinical to Clinical Translation: Utilizing plasma biomarkers to stratify patients and build confidence in human dose
*Building candidates to survive: High confidence in PK/PD and therapeutic index to test MOA in p